Bipartisan Bill to Allow Access to Approved Marijuana-Derivative Meds Heads to Gov’s Desk
Bipartisan legislation that Health & Human Services Committee Chairwoman Debbie Armstrong introduced with Rep. Monica Youngblood to allow New Mexicans access to FDA-approved marijuana-derivative medications passed the New Mexico Senate on Wednesday, and is now headed to the governor’s desk.
“New Mexicans deserve access to all the safe and effective medications available,” Armstrong said. “If a child suffering from epileptic seizures can be helped by an FDA-approved medication that is derived from marijuana, we must do the right thing by helping to ease that child’s suffering.”
Specifically, HB 139 amends the Controlled Substances Act and enacts a new section of state law to allow, without penalty, the “dispensing, possession, prescribing, storage or transport of a prescription drug that the United States food and drug administration has approved and that contains marijuana, a tetrahydrocannabinol derivative or a chemical derivative of tetrahydrocannabinol.”
Armstrong, whose daughter is one of the namesakes of the Lynn and Erin Compassionate Use Act, which legalized the use of medical cannabis in New Mexico, knows first-hand the importance of trying all safe measures to help a sick loved one.
“When my daughter Erin was fighting cancer, I did everything in my power to ensure she received the best possible care,” Armstrong said. “Now I want to make sure that all parents in New Mexico know that if their kid is sick, and there’s a marijuana-derivative medication that can help them, they will have access to that medication.”
HB 139 will now go to the governor’s desk to await further action. Because the bill passed in the last three days of the session, the governor has 20 days after the end of the session to either sign, veto or take no action (pocket veto) the bill.